

available at [www.sciencedirect.com](http://www.sciencedirect.com)[www.elsevier.com/locate/brainres](http://www.elsevier.com/locate/brainres)


---



---

**BRAIN  
RESEARCH**


---



---



---

**Research Report**
**Negative regulation of Vsx1 by its paralog Chx10/Vsx2 is conserved in the vertebrate retina**
**Anna M. Clark<sup>a,1</sup>, Sanghee Yun<sup>a,b,1</sup>, Eric S. Veien<sup>b</sup>, Yuan Y. Wu<sup>a</sup>, Robert L. Chow<sup>c</sup>,  
Richard I. Dorsky<sup>b,d</sup>, Edward M. Levine<sup>a,b,d,\*</sup>**
<sup>a</sup>Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA<sup>b</sup>Department of Neurobiology and Anatomy, University of Utah, USA<sup>c</sup>Department of Biology, University of Victoria, Victoria, B.C., Canada<sup>d</sup>Utah Brain Institute, Salt Lake City, USA

## ARTICLE INFO

## Article history:

Accepted 13 June 2007

Available online 18 June 2007

## Keywords:

Homeobox

Homeodomain

Development

Eye

Microphthalmia

Bipolar cell

## ABSTRACT

*Chx10/Vsx2* and *Vsx1* are the only Paired-like CVC (Prd-L:CVC) homeobox genes in the mouse genome. Both are expressed in the retina and have important but distinct roles in retinal development. Mutations in *Chx10/Vsx2* cause reduced retinal progenitor cell (RPC) proliferation and an absence of bipolar cells, while mutations in *Vsx1* impair differentiation of cone bipolar cells. Given their structural similarities and importance in retinal development, we sought to determine if a regulatory interaction exists between these genes and whether inactivation of both genes blocks initiation of retinal development. We found that *Chx10/Vsx2* binds to a specific sequence in the *Vsx1* 5'-intergenic region and represses the activity of a luciferase reporter under the control of the *Vsx1* promoter. This is consistent with our observation that there is an inverse relationship between the levels of *Chx10/Vsx2* and *Vsx1* immunostaining within the bipolar cell class. Furthermore, *Vsx1* mRNA is upregulated in the RPCs of *Chx10/Vsx2* deficient mice and zebrafish embryos injected with a *chx10/vsx2* morpholino. In mice deficient for both *Chx10/Vsx2* and *Vsx1* and zebrafish embryos co-injected with *chx10/vsx2* and *vsx1* morpholinos, the changes in embryonic retinal development and marker expression are similar in magnitude to embryos with *Chx10/Vsx2* loss of function only. From these studies, we propose that *Vsx1* is a direct target of *Chx10/Vsx2*-mediated transcriptional repression. Although *Vsx1* mRNA is upregulated in *Chx10/Vsx2* deficient RPCs, *Vsx1* does not genetically compensate for loss of *Chx10/Vsx2*, demonstrating that Prd-L:CVC genes, although important, are not absolutely required to initiate retinal development.

© 2007 Elsevier B.V. All rights reserved.

\* Corresponding author. John A. Moran Eye Center, 65 N. Medical Dr. Salt Lake City, UT 84132, USA. Fax: +1 801 587 8314.

E-mail address: [ed.levine@utah.edu](mailto:ed.levine@utah.edu) (E.M. Levine).

Abbreviations: Prd-L:CVC, Paired-like:CVC; HD, homeodomain; RPCs, retinal progenitor cells; NBL, neuroblast layer; MO, morpholino; orJ, ocular retardation J; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; DCL, differentiated cell layer; RPE, retinal pigmented epithelium; EOM, extraocular mesenchyme; OAR motif, orthopedia/aristaless/rax motif; RV motif, rinx/vsx1 motif; BS, Black Swiss

<sup>1</sup> Equal contributing authors.

## 1. Introduction

A multitude of homeobox genes is required for retinal development, from the initial patterning events of the optic vesicle to the completion of terminal differentiation (reviewed in Chow and Lang, 2001; Dyer, 2003; Fuhrmann et al., 2000a; Levine and Green, 2004; Lupo et al., 2000; see also De Melo et al., 2003). In many cases, paralogous homeobox genes retain close relationships as indicated by similarities in expression patterns and mutant phenotypes. It is not uncommon, however, for these genes to develop cross-regulatory networks and diverge in function (for examples, see Czerny et al., 1999; Plouhinec et al., 2005). Identifying these relationships is essential for sorting out the complex transcription factor networks driving retinal development.

Prd-L:CVC proteins comprise a subgroup of homeodomain (HD) proteins based on two distinguishing structural characteristics: the presence of a Paired-like HD with a glutamine at position 50 (Prd-L, Q<sub>50</sub>; Galliot et al., 1999), and a region of approximately 60 amino acids of unknown function positioned immediately C-terminal to the HD. This region of extended conservation is referred to as the CVC domain after the four genes from which it was originally identified, *ceh-10* (*C. elegans*; Svendsen and McGhee, 1995), and *vsx1* and *vsx2* (goldfish; Levine et al., 1994), and *Chx10* (mouse; Liu et al., 1994). Whereas *ceh-10* is the only identified Prd-L:CVC gene in *C. elegans*, essentially all vertebrate genomes examined to date have two Prd-L:CVC genes that parse into two ortholog clusters, *Chx10/Vsx2*-like and *Vsx1*-like, named after their founding members. It is likely that duplication of a single Prd-L:CVC gene occurred prior to the vertebrate radiation to give rise to the *Chx10/Vsx2*-like and *Vsx1*-like paralogs (Chow et al., 2001; Passini et al., 1998).

Two conserved features of Prd-L:CVC genes during development are their expression in interneurons and importance in differentiation. *ceh-10* is expressed in a restricted set of sensory interneurons and has a role in their fate specification (Altun-Gultekin et al., 2001; Svendsen and McGhee, 1995). In vertebrates, *Chx10/Vsx2* and *Vsx1* are expressed in interneuron populations in the spinal cord, hindbrain, and in retinal bipolar cells. Both genes are required for bipolar cell differentiation, although in different ways (see below). Biochemical studies also suggest a high degree of functional overlap between Prd-L:CVC proteins. *Chx10* and *Vsx1* proteins bind with high affinity to the same DNA sequence (Ferda Percin et al., 2000; Hayashi et al., 2000; Heon et al., 2002) and overexpression of human *CHX10* or *VSX1* protein represses transcription from the same heterologous reporter construct (Dorval et al., 2005). All Prd-L:CVC proteins contain an octapeptide motif that functions as a nuclear export signal (Knauer et al., 2005) and a nuclear localization signal (Kurtzman and Schechter, 2001). These motifs may work together to regulate the sub-cellular localization of Prd-L:CVC proteins.

Despite their close structural and biochemical relationships, *Chx10* and *Vsx1* differ in several ways. Sequences N-terminal of the HD and C-terminal of the CVC domain vary considerably and contain motifs not shared across the paralog groups such as the OAR motif in *Chx10* orthologs (named for *othopedia/aristaless/Rax*; Furukawa et al., 1997) and the RV

motif in *Vsx1* orthologs (named for *Rinx/Vsx1*; Hayashi et al., 2000). *Chx10* and *Vsx1* also differ in their expression patterns. *Chx10* expression (mRNA and protein) initiates during optic cup formation in presumptive retinal progenitor cells (RPCs) and remains expressed until RPCs exit the cell cycle and in the adult, *Chx10* is expressed in bipolar cells and a subset of Muller glia (reviewed in Levine and Green, 2004; see also Rowan and Cepko, 2004). *Vsx1* mRNA is detected during embryonic retinal development in several species (Chen and Cepko, 2000; D'Autilia et al., 2006; Passini et al., 1997, 1998). In contrast, *Vsx1* protein is first detected late in retinal development and is expressed in differentiating bipolar cells (Chow et al., 2001; Decembrini et al., 2006; Ohtoshi et al., 2001; this study). In the adult, *Vsx1* is expressed in a subset of cone bipolar cells.

Evidence for distinct contributions of *Chx10* and *Vsx1* to retinal biology is illustrated by their mutant phenotypes. Mutations in *Chx10* cause microphthalmia in humans (Bar-Yosef et al., 2004; Ferda Percin et al., 2000) and mice (Burmeister et al., 1996), and antisense-*chx10* RNA injected into zebrafish embryos causes a small eye phenotype (Barabino et al., 1997). Studies in *ocular retardation J (orf)* mice, which carry a spontaneously-derived nonsense mutation in the HD (Y176stop) of *Chx10* (*Chx10<sup>orf</sup>*; Burmeister et al., 1996; Theiler et al., 1976), show that in addition to a lack of bipolar cells, the *Chx10<sup>orf</sup>* homozygote (*Chx10<sup>orf/orf</sup>*) retina exhibits a profound decrease in RPC proliferation, a propensity to transdifferentiate along a pigmentation pathway, delays in embryonic neurogenesis, persistent neurogenesis in the adult retina, and an enrichment of adult ciliary epithelium derived retinal stem cells (Bone-Larson et al., 2000; Burmeister et al., 1996; Coles et al., 2006; Dhomen et al., 2006; Green et al., 2003; Horsford et al., 2005; Livne-Bar et al., 2006; Rowan et al., 2004; Rutherford et al., 2004).

On the other hand, retinal abnormalities associated with *Vsx1* mutations are considerably less severe and more restricted. Microphthalmia is not observed and retinal histology appears normal in *Vsx1* knockout mice (Chow et al., 2004; Ohtoshi et al., 2004). However, humans and mice with *Vsx1* mutations have abnormal photopic electroretinogram (ERG) profiles associated with cone bipolar cell dysfunction (Heon et al., 2002; Mintz-Hittner et al., 2004; Valleix et al., 2006). Consistent with this, a restricted set of cone bipolar cells fails to complete their differentiation even though the full cohort of bipolar cells appear to be specified in *Vsx1* knockout mice (Chow et al., 2004; Ohtoshi et al., 2004). Additionally, *Vsx1* mutations in humans are also associated with corneal dystrophies such as keratoconus, possibly because of a role in corneal wound repair that is independent from its retinal function (Barbaro et al., 2006).

Since *Chx10* and *Vsx1* have several features in common but also mediate distinct aspects of retinal development, we set out to determine if a regulatory interaction exists between *Chx10* and *Vsx1* to control their expression. We also wanted to determine if *Vsx1* promotes what remains of histogenesis in the *Chx10* deficient retina. Data presented here provide evidence that *Chx10* negatively regulates *Vsx1* expression by direct transcriptional control. However, once relieved from this regulation, *Vsx1* does not fill in for *Chx10* during embryonic retinal development.

## 2. Results


### 2.1. *Vsx1* is a candidate direct target of transcriptional repression by *Chx10*

We generated a polyclonal antiserum against a peptide corresponding to a unique sequence in the C-terminal variable region of mouse *Vsx1*. The *Vsx1* antisera detects nuclei positioned in the INL in a pattern consistent with previous reports of *Vsx1* expression in bipolar cells of the adult wild type retina, whereas retinal sections from adult *Vsx1* null mice (*Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup>) are devoid of any staining (Figs. 1A, B). Western blots from retinal lysates P14 and older show that the antiserum detects a band of approximately 39 kDa in the wild type retina, which is consistent with the predicted size of the endogenous *Vsx1* protein, and this band is absent in lysates from the *Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup> retina (Fig. 1C). A second band at 64 kDa is detected in both lysates and is therefore assumed to not originate from the *Vsx1* locus. In addition, embryonic retinal extracts contain a band of the same size as *Vsx1* that persists in the *Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup> lysates (data not shown). Importantly, immu-

nohistochemical detection of these ‘non-*Vsx1*’ proteins in cryosections is not apparent. These observations demonstrate the utilities and limitations of our antiserum for analyzing *Vsx1* expression in the mouse retina.

Using double-label indirect-immunofluorescence, we directly compared the expression patterns of *Chx10* and *Vsx1* in the postnatal mouse retina (Figs. 1D–I). As expected, both proteins were localized to cells in the outer half of the inner nuclear layer (INL; Figs. 1D–F). However, cells showing the brightest staining with each antibody segregated into distinct populations as indicated by the lack of yellow nuclei in the merged images (Figs. 1F, I). Closer examination (Figs. 1G–I) revealed that most cells with *Chx10* staining had little or no *Vsx1* staining (closed arrowheads); some cells with low *Chx10* staining had high *Vsx1* staining (arrows); and occasional cells with low *Chx10* staining also had low *Vsx1* staining (open arrowheads). These data show that *Chx10* and *Vsx1* can be co-expressed in the same cells but not in a manner in which both proteins are expressed at their highest levels.

Prior to bipolar cell differentiation, *Chx10* expression predominates. *Chx10* expression is activated to relatively high levels in RPCs at the earliest stages of optic cup formation



**Fig. 1** – Endogenous expression pattern of *Vsx1* and *Chx10* in postnatal retina. (A–C) The specificity of *Vsx1* antibody was determined by immunohistochemistry (A, B) and by western blot analysis (C) on retinal samples from wild type (+/+) and *Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup> ( $\tau$ lacZ/ $\tau$ lacZ) mice at P14 or older. The nuclear pattern of *Vsx1* staining in the INL is observed in wild type (A) and absent in *Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup> retina (B). (C) A band of the expected size (approximately 39 kDa) is present in wild type and absent in *Vsx1* <sup>$\tau$ lacZ/ $\tau$ lacZ</sup> P14 retinal lysates. Another band of approximately 64 kDa is observed in both lysates.  $\beta$ -Actin was used as a loading control. (D–I) Confocal images showing *Vsx1* (D, G) and *Chx10* (E, H) expression patterns in P8 wild type retina. Merged images are shown in F and I. Arrows point to examples of cells with high *Vsx1* and low *Chx10* expression. Arrowheads point to examples of cells with low *Vsx1* and high *Chx10* expression. The open arrowhead points to a cell that co-expresses both proteins at low levels. Asterisks in H and I indicate a staining artifact. Scale bars: 40  $\mu$ m. Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.


whereas *Vsx1* is expressed at low levels, if at all. Two exceptions are the *Vsx1* orthologues *Chx10-1* in chick and *vsx1* in *Xenopus*, whose transcripts are robustly detected in RPCs (Chen and Cepko, 2000; D'Autilia et al., 2006). Even so, the sum of the expression data suggests a regulatory mechanism exists to keep *Vsx1* expression at low levels in *Chx10* expressing cells. Consistent with this, *Vsx1* mRNA is upregulated in the newborn *Chx10<sup>orj/orj</sup>* retina (Fig. 2A).

Since *Chx10* can act as a transcription repressor, we asked whether *Vsx1* is a target of *Chx10*. Based on a collection of known *Chx10* binding sequences, Dorval and colleagues defined the following sequence as a consensus for *Chx10* binding: PyTAATTPuPu (Py, pyrimidine; Pu, purine; Dorval et al., 2006). A scan of genomic DNA associated with the *Vsx1* locus revealed two potential sites: one at –576 nt (TTAATTAG) and another at –1275 nt (CTAATTGG) relative to the *Vsx1* transcriptional start site as predicted by ensembl ([www.ensembl.org](http://www.ensembl.org)). *Chx10* preferentially binds at or near the site positioned at –576 as determined by chromatin immunoprecipitation (ChIP) using native neonatal retinal lysates (Fig. 2B). Consistent with this, electrophoretic mobility shift assays (EMSA) show that in vitro translated *Chx10* binds to the <sup>32</sup>P-labeled *Vsx1* probe containing the site at –576 (*Vsx1<sub>wt</sub>*; Fig. 2C). The binding of *Chx10* to this probe is diminished with unlabeled *Vsx1<sub>wt</sub>* oligonucleotide in excess, but not by a variant containing a mutated *Chx10* binding site (*Vsx1<sub>mut</sub>*). These data show that the *Chx10* binding is dependent on the sequence con-


forming to the consensus. Addition of *Chx10* antibody to the binding reaction resulted in a supershifted band, which indicates that the band observed in these assays is due to the association of *Chx10* protein with the *Vsx1<sub>wt</sub>* probe.

To further explore a potential transcriptional regulation of *Vsx1* by *Chx10*, a *Chx10* expression construct was co-transfected with the pGL3E luciferase reporter construct into HEK293 cells (Fig. 3). Approximately 2.6 kb of *Vsx1* genomic DNA containing the two putative *Chx10* binding sites (–1275 and –576), the *Vsx1* promoter, and 0.4 kb of exon 1 was cloned directly upstream of the luciferase cDNA. Consistent with its role as a transcriptional repressor, we found that *Chx10* significantly inhibits luciferase activity (*p*-value < 0.0001). We also tested a variant of *Chx10* containing an arginine to glutamine replacement at residue 200 (*Chx10<sup>R200Q</sup>*). This mutation resides in the DNA binding helix of the HD (residue 53) and eliminates high affinity binding to *Chx10* consensus sites and causes microphthalmia when inherited in a homozygous manner in humans (Ferda Percin et al., 2000). *Chx10<sup>R200Q</sup>* does not repress expression from the construct containing both *Chx10* binding sites (pGL3E-*Vsx1<sup>wt</sup>*; *p*-value 0.076). Additionally, the level of reporter activity is significantly higher in the presence of *Chx10<sup>R200Q</sup>* compared to *Chx10* (*p*-value < 0.0001).

To determine the importance of the *Chx10* consensus sites for transcription from the *Vsx1* promoter, we tested reporter constructs with mutations in the sites at –576 and –1275, either alone or in combination. *Chx10* still inhibits luciferase activity



**Fig. 2** – *Vsx1* mRNA levels are increased in the *Chx10<sup>orj</sup>* retina and *Chx10* binds to a site upstream of the *Vsx1* gene in vivo and in vitro. (A) RT-PCR amplification products using wild type and *Chx10<sup>orj/orj</sup>* P0 retinal RNA and primers for *Vsx1* and *Gapdh*. (B) Chromatin immunoprecipitation (ChIP) assay. Native chromatin-protein lysates were isolated from E16, P0, and P1 wild type retinas and immunoprecipitated with a sheep polyclonal *Chx10* antibody (*Chx10* ab). The precipitated chromatin was amplified by PCR using two non-overlapping primer sets that flank sequences conforming to the *Chx10* consensus at positions –576 and –1275 relative to the *Vsx1* transcription start site. The input lane shows amplification from chromatin not subjected to immunoprecipitation. Sheep IgG or H<sub>2</sub>O were used as negative controls. (C) Electrophoretic mobility shift assays (EMSA). Lane 1 shows the pattern of [<sup>32</sup>P]-labeled oligonucleotide probe containing the *Chx10* consensus site at –576 (*Vsx1<sub>wt</sub>*) without addition of *Chx10* protein. Lane 2 shows the resulting band pattern when in vitro translated *Chx10* protein is mixed with the [<sup>32</sup>P]-labeled *Vsx1<sub>wt</sub>* probe in a binding reaction. Lane 3 and 4 show results of competition assays when unlabeled *Vsx1<sub>wt</sub>* oligonucleotides are added in excess to the binding reaction (*Vsx1<sub>wt</sub>* comp (Lane 3) and *Vsx1<sub>mut</sub>* comp (Lane 4)). Addition of *Chx10* ab to the binding reaction (lane 5) results in a supershifted band. The line over the sequences shown indicates the position of the *Chx10* binding site sequence and asterisks indicate the nucleotide changes in the *Vsx1<sub>mut</sub>* oligonucleotide.



**Fig. 3 – Chx10 expression inhibits luciferase activity in a DNA-binding dependent manner and Chx10 binding sites near the Vsx1 promoter are required for high luciferase activity in HEK293 cells. (A)** Schematic diagrams of reporter constructs with Vsx1 promoters that contain both Chx10 binding sites (pGL3E-Vsx1<sup>wt</sup>) or with site specific mutations in these sites (pGL3E-Vsx1<sup>mut1</sup>, mutated at -1275; pGL3E-Vsx1<sup>mut2</sup>, mutated at -576; pGL3E-Vsx1<sup>mut3</sup>, mutated at both sites). Region bracketed corresponds to Vsx1 genomic DNA and numbering is relative to predicted Vsx1 transcription start site. **(B)** HEK293 cells were transfected with each reporter construct, pRL-TK to monitor transfection efficiency, and either an empty expression vector (pCMV; white bars), pCMV-Chx10 (gray bars), or pCMV-Chx10<sup>R200Q</sup> (black bar). Relative luciferase activity is normalized to the pGL3E-Vsx1<sup>wt</sup> co-transfected with empty expression vector (the first white bar) and is arbitrarily assigned as 100% activity. The standard deviation for each test condition is shown. Statistical significances (*p*-values) were tested by two-way repeated measures ANOVA and Tukey tests for multiple comparisons with values transformed by log2. \**p*<0.001 (*p*-value of each gray bar compared to each respective white bar); \*\**p*=0.0001; ++*p*<0.001 (*p*-value of pGL3E-Vsx1<sup>mut3</sup> (last white bar) compared to other reporter constructs (white bars)). Abbreviations: Ex1, exon 1 of Vsx1; LUC, luciferase cDNA; (A)<sub>n</sub>, SV40 late poly(A) signal; E, SV40 enhancer.

in the context of the single site mutations (mut1 and mut2; *p*-value<0.001) and inhibition is not completely eliminated when both sites are mutated (mut3). Interestingly, the basal level of

luciferase activity is significantly lower with the mut3 reporter than observed for the other promoters (wt, mut1, and mut2; *p*-value<0.001, the same value for all three comparisons).


Although Chx10 continues to inhibit luciferase activity in the absence of both Chx10 binding sites (see Section 3.1), our results indicate that both of these sites are necessary for high levels of transcription from the *Vsx1* promoter and adjacent regions, and the sum of our observations support the model that Chx10 is a direct negative regulator of *Vsx1* transcription.

## 2.2. *Vsx1* fails to compensate for the loss of Chx10 function during embryonic retinal development

Although histogenesis is severely affected by the absence of Chx10, several aspects of retinal development are still evident.

This suggests Chx10 is not absolutely required and *Vsx1* may partially compensate for the Chx10 deficiency. The upregulation of *Vsx1* mRNAs in the *Chx10<sup>0/0</sup>* retina (Fig. 2A) supports this idea. Therefore, we crossed *Chx10<sup>0/0</sup>* mice with *Vsx1<sup>τlacZ</sup>* mice to produce compound mutants and compared the resultant phenotypes.

During normal retinal development in mice, histogenesis is well underway by E14.5. RPC proliferation and differentiation into postmitotic neurons are robust as indicated by the expression patterns of PCNA and *CycD1* in proliferating RPCs found in the neuroblast layer (NBL; Figs. 4A, C) and Tuj1 in differentiating neurons that are scattered through the NBL



**Fig. 4** – Immunohistochemical analysis of E14.5 eyes from wild type and *Vsx1<sup>τlacZ/τlacZ</sup>* mice. Expression patterns of PCNA (A, B), *CycD1* (C, D), Pax6 (E, F), and Tuj1 (G, H) proteins in wild type (A, C, E, G) and *Vsx1<sup>τlacZ/τlacZ</sup>* (B, D, F, H) eyes. All panels with an \* show the images in the boxes from each corresponding panel. These images were rotated such that the apical surface of the retina is pointed down. Scale bars: 100 μm. Abbreviations: RPE, retinal pigmented epithelium; R, retina; EOM, extraocular mesenchyme; L, lens; C, cornea; NBL, neuroblast layer; DCL: differentiated cell layer.

and accumulating in the nascent ganglion cell layer and presumptive INL (collectively defined here as differentiated cell layer, DCL; Fig. 4G). Pax6, which is important for optic vesicle development, RPC proliferation, and maintenance of the multipotential-state in RPCs (reviewed in Ashery-Padan and Gruss, 2001), is expressed initially in RPCs and subsequently shifts to differentiating neurons. At E14.5, Pax6 is detected in most if not all cells, and appears to be detected at higher levels in differentiated cells compared to RPCs (Fig. 4E). Compared to the wild type retina, overall ocular morphology and expression of PCNA, CycD1, Pax6, and Tuj1 are unaffected in the  $Vsx1^{\tau lacz/\tau lacz}$  retina (Figs. 4B, D, F, H). Consistent with these observations, Chx10 expression appears normal in the  $Vsx1^{\tau lacz/\tau lacz}$  retina (data not shown). In the  $Chx10^{orj/orj}$  mouse,

overall eye size is reduced, but retinal expression of PCNA is still abundant (Fig. 5A). CycD1 is also expressed but in a more dispersed pattern compared to wild type and  $Vsx1^{\tau lacz/\tau lacz}$  retinas (Fig. 5C). Tuj1 expression is more centrally restricted (Fig. 5G) consistent with a delay in neurogenesis (Bone-Larson et al., 2000; Rutherford et al., 2004; Green et al., submitted). Pax6 is widely expressed in a pattern consistent with RPCs, and this could be due to developmental delay (Fig. 5E). Compared to the  $Chx10^{orj/orj}$  mouse, ocular morphology and the expression patterns of the markers analyzed are similar in the  $Chx10^{orj/orj}$ ,  $Vsx1^{\tau lacz/\tau lacz}$  compound mutant (Figs. 5B, D, F, H). Although retinal development appears enhanced in the compound mutant, the phenotype is within the range of variation observed for  $Chx10^{orj/orj}$  single mutants. From these obser-




Fig. 5 - Immunohistochemical analysis of E14.5 eyes from  $Chx10^{orj/orj}$  and  $Chx10^{orj/orj}$ ,  $Vsx1^{\tau lacz/\tau lacz}$  mice. Expression patterns of PCNA (A, B), CycD1 (C, D), Pax6 (E, F), and Tuj1 (G, H) proteins in  $Chx10^{orj/orj}$  (A, C, E, G) and  $Chx10^{orj/orj}$ ,  $Vsx1^{\tau lacz/\tau lacz}$  (B, D, F, H) eyes. All panels with an \* show the images in the boxes from each corresponding panel. These images were rotated such that the apical surface of the retina is pointed down. Scale bars: 100  $\mu$ m.

variations, we conclude that *Vsx1* is dispensable in early retinal development and does not compensate for the loss of *Chx10*.

Marker expression was examined at P0 to determine whether *Vsx1* compensates for the loss of *Chx10* in neonatal RPCs (Fig. 6). The expression patterns of PCNA, CycD1, and Tuj1 in the *Vsx1*<sup>lacz/lacz</sup> retina are similar to wild type (Figs. 6A, B, E, F, I, J), and the expression of these markers in the *Chx10*<sup>orj/orj</sup>, *Vsx1*<sup>lacz/lacz</sup> compound mutant retina is similar to the *Chx10*<sup>orj/orj</sup> single mutant (Figs. 6C, D, G, H, K, L). We also examined the expression of *Brn3b*, which marks a major fraction

of the retinal ganglion cell population (RGCs; Xiang et al., 1993). Whereas *Brn3b*-positive cells are observed in all genotypes (Figs. 6M–P), the *Chx10*<sup>orj/orj</sup> and *Chx10*<sup>orj/orj</sup>, *Vsx1*<sup>lacz/lacz</sup> mutants showed obvious dispersion of these cells into the NBL. The cause of this dispersion is not known, but possibilities include the delay in neurogenesis, migration defects, or lamination defects. Importantly, these observations extend our finding that *Vsx1* is largely dispensable for retinal development through birth, either in the presence or absence of *Chx10*.





Fig. 6 – Immunohistochemical analysis of P0 eyes. Expression patterns of PCNA (A–D), CycD1 (E–H), Tuj1 (I–L), and Brn3b (M–P) in wild type (A, E, I, M), *Vsx1*<sup>lacz/lacz</sup> (B, F, J, N), *Chx10*<sup>orj/orj</sup> (C, G, K, O), and *Chx10*<sup>orj/orj</sup>, *Vsx1*<sup>lacz/lacz</sup> (D, H, L, P) eyes. Scale bar: 40  $\mu$ m.



To determine whether this is a common feature of vertebrate retinal development, we performed similar experiments in zebrafish (Fig. 7). Translation and splice blocking morpholino oligonucleotides (MO) targeted against *chx10* and *vsx1*, respectively, were injected into one-cell stage zebrafish and embryos were examined at 24 hpf, a stage of development when RPC proliferation is robust, but neurogenesis has not yet begun. Fig. 7A shows that the *vsx1* MO blocks splicing of *vsx1* mRNA in a dose dependent manner. To assess the effects of

the MOs on retinal development, the expression patterns of *vsx1*, *cycD1*, and *pax6a* were examined by in situ hybridization (Figs. 7B–M) and the sum of our observations on *vsx1* and *cycD1* expression are shown in Figs. 7N and O. *Chx10* knock-down led to an increase in *vsx1* expression specifically in the eye, as well as to a decrease in eye size (Figs. 7B, C). An eye-specific decrease in *cycD1* expression was also observed in *chx10* morphant embryos (Figs. 7F, G). *Vsx1* knockdown had little or no effect on the expression of *vsx1* (Fig. 7D), *cycD1* (Fig.



**Fig. 7** – *Vsx1* does not compensate for loss of *Chx10* in zebrafish. (A) RT-PCR showing accumulation of unspliced *vsx1* mRNA in a dose-dependent manner following injection of a splice-blocking morpholino (MO) against *vsx1*. Lane 1 shows molecular weight marker. Lanes 2, 4, and 6 show spliced and unspliced *Vsx1* RNA derived from zebrafish embryos injected with the indicated morpholinos. Lanes 3, 5, and 7 represent no template controls (reverse transcriptase omitted). (B–M) In situ hybridizations for *vsx1* (B–E), *cycD1* (F–I), and *pax6a* (J–M) in 24 h embryos that were uninjected (B, F, J), injected with 1.5 ng *chx10* MO (C, G, K), 15 ng *vsx1* MO (D, H, L), or co-injected with 1.5 ng *chx10* and 15 ng *vsx1* MOs (E, I, M). Eyes in F–I are within the dotted lines. (N, O) Quantification of relative changes in expression levels for *vsx1* and *cycD1* mRNAs among morphant embryos (n, number of embryos analyzed).

7H) or *chx10* (not shown). *pax6a* expression was unaffected relative to eye size in all morphant embryos (Figs. 7J–M), indicating that eye identity was not perturbed. If *Vsx1* compensates for loss of *Chx10*, then it would be expected that *cycD1* expression and eye size would be more severely affected in *chx10*, *vsx1* double morphant embryos compared to *chx10* single morphants. We did not observe such phenotypes (Figs. 7G, I), suggesting that, as in the mouse, *Vsx1* does not compensate for loss of *Chx10* in zebrafish eye development.

### 3. Discussion

#### 3.1. Regulation of *Vsx1* by *Chx10*

In this study, we present evidence supporting a model in which *Chx10* directly regulates expression of *Vsx1* mRNA through a mechanism of transcription repression. *Chx10* preferentially binds at or in close proximity to the *Chx10* consensus sequence that is positioned close to the transcription start site (–576) *in vivo* and requires this site for binding *in vitro*. *Chx10* inhibits luciferase activity when transcription is under the control of the *Vsx1* promoter, which is consistent with the proposed role of *Chx10* as a transcription repressor. We found that *Chx10*<sup>R200Q</sup> does not significantly repress reporter activity, suggesting that the ability of *Chx10* to repress transcription is largely dependent on high affinity binding to sequences conforming to the consensus. These findings are in agreement with a previous report showing that mutation of another residue in the DNA binding helix of *Chx10* (N51A) also reduces the efficiency of transcriptional repression by *Chx10* (Dorval et al., 2005, 2006).

Interestingly, mutation of both consensus sites in the *Vsx1* genomic sequence (mut3) causes a significant drop in basal reporter activity. Since *Chx10* is a more effective repressor when it has high affinity for its consensus site, it is possible that *Chx10* inhibits transcription by competing with activators for the same sites.

We found that *Chx10* still inhibits luciferase activity in the absence of the two consensus sites (mut3). Although it is tempting to propose a mechanism of *Chx10* repression that is independent of its binding to sequences fitting the consensus, two additional *Chx10* consensus sites are present in the SV40 enhancer region of the reporter construct and it is likely that the repressive effect of *Chx10* on the mut3 reporter is mediated through these sites. Currently, the simplest model is that *Chx10* inhibits *Vsx1* transcription by a mechanism that depends on binding to its consensus sequence, and the site at –567 is sufficient for *Chx10* binding and negative regulation of *Vsx1* transcription *in vivo*.


The expression patterns of *Chx10* and *Vsx1* during retinal development provide further evidence of a regulatory interaction. When *Chx10* expression is high in RPCs, *Vsx1* is low or nonexistent. Additionally, *Vsx1* mRNA levels are increased in the *Chx10* deficient retina of mice and zebrafish. Interestingly, the chick *Vsx1* ortholog, *Chx10-1*, is expressed at high levels, and *Chx10* appears to be expressed at relatively lower levels in RPCs (Chen and Cepko, 2000). A simple scenario to explain this apparent reversal in expression profile is that *Chx10* regulation changed in the developing chick retina such that *Chx10* levels

decreased, thereby allowing *Vsx1* levels to increase. *Xenopus vsx1* is also expressed at high levels in RPCs, but the status of *Chx10* expression is not known (D'Autilia et al., 2006).

In the postnatal and mature retina of all vertebrates examined, *Chx10* and *Vsx1* mRNAs are expressed in bipolar cells, but their patterns are not in perfect correspondence. Where examined, *Chx10* is expressed at the earliest stages of bipolar cell differentiation and remains expressed in rod bipolar cells and a large subset of cone bipolar cells. *Vsx1* expression is subsequently activated and is restricted to a subset of cone bipolar cells (off-cone). We found that the *Chx10* and *Vsx1* proteins can be co-expressed in the same cells of the postnatal retina, but in a complementary fashion: cells expressing high levels of *Chx10* express *Vsx1* at low levels, and vice versa, and these relationships are not time dependent (R.L. Chow, ms in prep). While these observations support the model that *Chx10* antagonizes *Vsx1* expression, they also leave open the possibility that *Vsx1* could antagonize *Chx10* expression as well.

Further insight into the transcriptional control of *Chx10* and *Vsx1* is gained from expression studies in *Chx10* and *Vsx1* single mutant mice. *Chx10* mRNA expression in *Chx10*<sup>orf</sup> mice is not altered, suggesting that *Chx10* does not regulate its own expression (Rowan and Cepko, 2004; Rowan et al., 2004; Rutherford et al., 2004; Green et al., submitted). Furthermore, the upregulation of *Vsx1* mRNA in the developing *Chx10*<sup>orf</sup> retina does not appear to have a significant effect on *Chx10* expression as well, either because *Vsx1* does not regulate *Chx10* levels or its expression is not at sufficient levels to exert an effect. In contrast, *Vsx1* may negatively regulate its own expression in bipolar cells (Chow et al., 2004; Ohtoshi et al., 2004).

The sum of these findings suggests a hierarchical transcriptional network shown in Fig. 8. In this model, *Chx10* expression is not regulated either by *Chx10* or *Vsx1* in RPCs. However, RPCs are competent to express *Vsx1* but are inhibited from doing so by cross-regulation from *Chx10*. Activation and/or maintenance of *Chx10* expression may be mediated by interaction with the surface ectoderm (Hyer et al., 1998; Nguyen and Arnheiter, 2000) and/or exclusion of the extraocular mesenchyme (Fuhrmann et al., 2000b). Transcriptional regulation of *Chx10* appears to be complex and involve multiple enhancers (Rowan and Cepko, 2004, 2005) and candidate pathways and factors for promoting *Chx10* expression include Fgf signaling, Bmp signaling, Hes activity, Mab21l2, and Rx3 (Gotoh et al., 2004; Hatakeyama et al., 2004; Horsford et al., 2005; Loosli et al., 2001; Murali et al., 2005; Nguyen and Arnheiter, 2000; Winkler et al., 2000; Yamada et al., 2004). However, the mechanisms that account for their regulation of *Chx10* are not known nor is it known whether any of these candidates act in a direct manner. *Pou3f2* (Brn2) was recently identified as a candidate direct regulator of *Chx10* expression in late RPCs and early, differentiating bipolar cells (Rowan and Cepko, 2005). In this case, however, it is not known if *Pou3f2* is sufficient or required for *Chx10* expression. As bipolar cells mature, *Chx10* is downregulated in a subset of cone bipolar cells and *Vsx1* is upregulated, albeit in a controlled manner because of *Vsx1*-mediated autoregulation (Chow et al., 2001, 2004; Ohtoshi et al., 2004). The factors that maintain *Chx10* expression in mature bipolar cells are



**Fig. 8 – Proposed regulatory network for Chx10 and Vsx1 in RPCs and bipolar cells. Large arrows represent the indicated developmental transitions. See Section 3.2 for details.**

not known, nor is it known whether negative regulators of Chx10 or positive regulators of Vsx1 feed into the proposed network.

### 3.2. Prd-L:CVC genes in embryonic retinal development

The increase in Vsx1 mRNA in the developing *Chx10<sup>orj/orj</sup>* mouse retina and zebrafish *chx10*-morphant retina prompted us to test whether Vsx1 has an effect on retinal development prior to bipolar cell differentiation. Since the HD and CVC domain of Chx10 and Vsx1 are similar and both proteins act as transcription repressors with overlapping DNA binding specificities, we wanted to know if the residual histogenesis occurring in the *Chx10<sup>orj/orj</sup>* retina is dependent on Vsx1. In mice and zebrafish deficient for both Chx10 and Vsx1, we did not observe any significant changes in retinal development compared to Chx10 deficient animals. Additionally, Vsx1 deficiency did not have any obvious effect on retinal development compared to wild type animals. From these observations, we conclude that Vsx1 does not contribute to embryonic retinal development and that the residual histogenesis occurring in the Chx10 deficient retina is not dependent on Prd-L:CVC genes in general since Chx10 and Vsx1 are the only known Prd-L:CVC genes in mouse and zebrafish.

These findings begin to provide insight into how Chx10 fits into the hierarchy of transcription factors important for early retinal development. Homeobox genes such as Six3, Rx, Pax6, and Lhx2 are expressed in the developing eye field and are necessary for optic cup formation in mice or humans. In each case, genetic inactivation results in anophthalmia, which is a complete failure of eye development (reviewed in Fitzpatrick and van Heyningen, 2005; Graw, 2003). In addition, these genes induce ectopic eyes in *Xenopus* when expressed together and in combination with *six6/optx2*, *tlh*, and *ET* (Zuber et al., 2003). As a result of these features, these genes have been termed the *eye field transcription factors* (EFTFs) and they are thought to form a network analogous to the *retinal determination gene network* (RDGN) in *Drosophila* (reviewed in Hanson, 2001). How Chx10 fits into this paradigm is not known. At present, it is the earliest expressed and most specific marker of the neural retina domain and its inactivation produces a severe and highly penetrant microphthalmia. Since genetic inactivation of both Chx10 and Vsx1 does not push the eye phenotype towards anophthalmia, it is now clear that Vsx1 is not com-

pensating for loss of Chx10 in early eye development and Chx10 has a role distinct from, but possibly downstream of EFTFs such as Six3, Rx, Pax6, and Lhx2.

### 3.3. Functional overlap between Chx10 and Vsx1

We did not observe a change of phenotype in *Chx10<sup>orj/orj</sup>*, *Vsx1<sup>rlacz/rlacz</sup>* compound mutants and *chx10, vsx1* double morphants compared to the *Chx10<sup>orj/orj</sup>* single mutants and *chx10* single morphants, respectively. While this suggests that Chx10 and Vsx1 do not have overlapping functions such as shared transcriptional targets, it is premature to conclude this since we do not know if Vsx1 protein is upregulated to sufficient levels in RPCs lacking Chx10. Even in *Xenopus*, where *vsx1* mRNA is highly expressed in RPCs (D'Autilia et al., 2006), post-transcriptional regulation is thought to keep Vsx1 protein levels at a minimum until bipolar cell formation (Decembrini et al., 2006). Thus, it is still not known if the functional overlap between Chx10 and Vsx1 shown in biochemical studies has significance in retinal development.

Chx10 overexpression inhibits photoreceptor differentiation and several phototransduction genes are candidate direct transcriptional targets of negative regulation by Chx10 (Dorval et al., 2006; Livne-Bar et al., 2006; Toy et al., 2002). These findings combined with the shared DNA binding characteristics and repressive activities of Chx10 and Vsx1 led to the proposal that these genes could function in bipolar cells to prevent inappropriate expression of photoreceptor genes (Dorval et al., 2006). While possible, this scenario is not likely to fully explain how Chx10 and Vsx1 function in bipolar cells. In the Vsx1 deficient mouse retina, several markers of bipolar cells are downregulated in cells that normally express Vsx1 (Chow et al., 2004; Ohtoshi et al., 2004). However, Chx10 remains expressed in the same cells. This suggests that Chx10 is not able to compensate for Vsx1 in cone bipolar cells and that Chx10 and Vsx1 have distinct functions, possibly by targeting different genes for regulation.

Although more work is needed to understand more fully the functional relationships between Chx10 and Vsx1, our work shows that a regulatory relationship has evolved between these paralogs that could allow for overlap of some functions, but at the same time, also allow for functional divergence that contributes to the complex networks driving retinal development.

## 4. Experimental procedures

### 4.1. Mouse strains

Chx10 null mice (*Chx10<sup>0/0</sup>*) were purchased from Jackson Labs. *Vsx1* null mice (*Vsx1<sup>lacZ</sup>*; Chow et al., 2004) were mated to *Chx10<sup>orJ</sup>* mice to produce compound mutants. PCR based genotyping was done as previously described (Burmeister et al., 1996; Chow et al., 2004). The *Chx10<sup>orJ</sup>* and *Vsx1<sup>lacZ</sup>* alleles originated from 129 genetic backgrounds and the mice analyzed for this study are mixed hybrids. For all animals used in this study, efforts were made to minimize pain and discomfort during procedures and in preparing for euthanasia.

### 4.2. *Vsx1* polyclonal antibody production

15-Amino acid peptide, HLKKGANKDEDGPER (position 301 to 315), was synthesized and conjugated to KLH at the University of Utah peptide synthesis core facility. Polyclonal antibodies were prepared commercially (Harlan Bioproducts, Inc. Indianapolis IN). IgG fraction was purified using SulfoLink Kit according to manufacturer's instructions (Pierce, Rockford, IL).

### 4.3. Immunohistology

Mouse embryonic heads, postnatal whole eyes or isolated retinas were dissected in Hanks buffered saline solution (HBSS) and immediately fixed in 4% neutral-buffered formalin (PFA) for various lengths of time varying from 20 min at room temperature to overnight at 4°C. Following fixation, tissue was washed twice with PBS, then replaced with sucrose gradient and finally embedded in OCT (Sakura Finetek, Torrance, CA). 12 μm thick cryosections were used for immunostaining. The primary antibodies used were: rabbit anti-*Vsx1* (1:200; this study); sheep anti-*Chx10* (1:300; Exalpha Biologicals, Boston, MA); rabbit anti-*CycD1* (1:400; Lab Vision, Fremont, CA); rabbit anti-*Pax6* (1:300; Mastick et al., 1997); mouse monoclonal anti-*PCNA* (clone PC10; 1:500; Dako, Denmark); goat anti-*Brn3b* (1:50; Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-neuronal class III tubulin (*Tuj1*; 1:4000; Covance, Richmond, CA). Primary antibodies were followed with species-specific secondary antibodies conjugated to either Alexa Fluor 488 or Alexa Fluor 568 (Invitrogen/Molecular Probes, Eugene, OR).

### 4.4. Western blots

Mouse retinas were dissected in HBSS and stored at -80 °C. Frozen retinas were resuspended in a lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 1% Triton X-100) complemented with protease inhibitors (Complete mini tablets, Roche, Indianapolis, IN) and sonicated on ice. Protein concentration was determined by a BCA protein assay (Pierce Biotechnology, Rockford, IL). 20 μg of protein lysates were subsequently run on 12% SDS PAGE, then transferred to nitrocellulose membranes. Blots were incubated with antibodies diluted in blocking buffer (5% dry milk, 0.04% Tween-20, TBS pH 7.6). Primary antibodies included rabbit anti-*Vsx1*, mouse anti-β-Actin (Chemicon, Temecula, CA). Detection was performed using SuperSignal West Dura (Pierce Biotechnol-

ogy, Rockford, IL) and documented by ChemiDoc XRS imaging system (Bio-Rad, Hercules, CA).

### 4.5. RT-PCR of mouse RNA

Total RNA was extracted from P0 Black Swiss (BS) wild type and *Chx10<sup>orJ</sup>* retinas by using Trizol (Invitrogen, Carlsbad, CA). The concentration of total RNA was assessed by spectrophotometry and adjusted to the same level among samples. First-strand cDNA was synthesized by using M-MuLV Reverse Transcriptase and Oligo(dT)<sub>18</sub> (Fermentas, Hanover, MD). RT-PCR was carried out in a 30-μl reaction mixture. RT-PCR for a housekeeping gene (*Gapdh*) was used as a control (22 cycles) to normalize the concentration of the cDNA samples (primer sequences available on request). RT-PCR for *Vsx1* was performed with different amounts of cDNA (4, 2 or 1 μl) to estimate an appropriate number of cycles to amplify in the linear range (data not shown). The primers for *Vsx1* were: 5'-GGATGAGGATGGACCTGAGA-3' and 5'-AGGTGTTTTGCCAGCTTTGG-3'. PCR conditions were: 94 °C 30 s, 55 °C 30 s and 72 °C 30 s for 30–33 cycles. The size of the product is 208 bp.

### 4.6. Chromatin immunoprecipitation (ChIP)

Retinas from E16.0, P0 or P1 BS wild-type animals were dissected and cut into small pieces and then fixed in 1% formaldehyde for 15 min at room temperature. Following crosslinking, tissues were washed and sonicated to shear the DNA to lengths between 200 and 1000 bp. Sonicated supernatants were precleared with salmon sperm DNA (Invitrogen)/Protein G agarose beads (Roche, Indianapolis, IN), and incubated overnight at 4 °C with 5 μl sheep anti-*Chx10* antibody (Exalpha Biologicals, Boston, MA) or sheep IgG (Sigma, St. Louis, MO). The chromatin-antibody complex was collected with salmon sperm DNA/Protein G agarose. Cross-linking was reversed with 5M NaCl at 65 °C for 4 h. DNA was purified by QIAquick PCR purification kit (QIAGEN, Valencia, CA). 4 μl IP DNA was employed for PCR amplification for potential *Chx10* binding sites in *Vsx1* promoter (-576 and -1275). The following primers were used: *Vsx1* (-567): 5'-AGTTGTAAGCTGCCCTGTGG-3' and 5'-CCTGACTGGCAGC-TAGGAAT-3'. *Vsx1* (-1275): 5'-GCCGAAATTTGGATTTACGA-3' and 5'-TGGATGAGTGGGGAGAAATC-3'.

### 4.7. Electrophoretic mobility shift assays (EMSA)

pET26b-*chx10* plasmids were in vitro translated using rabbit reticulocyte lysates (Promega, Madison, WI). 2 pmol single-strand probes were end-labeled by T4 kinase (Invitrogen) with [<sup>32</sup>P]ATP (MP Biologicals, Solon, OH) and were purified using BioSpin6 column (Bio-Rad, Hercules, CA). The probes were boiled for 5 min at 95 °C and cooled to room temperature for 3 h to form double-stranded probes. Probe sequences were: *Vsx1* wild type (*Vsx1<sub>wild</sub>*), top strand: 5'-GCGTTTTAATTAGCTCCAGTTTCA; *Vsx1* mutant (*Vsx1<sub>mut</sub>*), top strand: 5'-GCGTTTTCTTAGCTCCAGTTTCA. EMSA assays were performed as described by (Dorval et al., 2005). Gels were dried and visualized with phosphorimager (Bio-Rad, Hercules, CA).

#### 4.8. Luciferase assays

HEK293 cells were transfected with 0.04 µg reporter construct, 0.02 µg pRL-TK and either 0.2 µg pCMV-Chx10 or pCMV-Chx10<sup>R200Q</sup> using the lipofectamine method according to the manufacturer's instructions (Invitrogen, Carlsbad, CA). Reporter constructs were designed as follows: pGL3E-Vsx1<sup>wt</sup> (wild type Vsx1 promoter), pGL3E-Vsx1<sup>mut1</sup> (Vsx1 promoter mutated in –1275 Chx10 binding site), pGL3E-Vsx1<sup>mut2</sup> (Vsx1 promoter mutated in –576 Chx10 binding site) and pGL3E-Vsx1<sup>mut3</sup> (Vsx1 promoter mutated in both –1275 and –576 Chx10 binding sites).

Cell lysates were prepared 24 h after transfection. The activities of firefly and Renilla luciferase were assayed using a Dynex Technologies MRX Revelation microplate reader (Dynex Technologies, Denkendorf, Germany) using 100 µl D-luciferin reagent and 100 µl coelenterazine (Biotium, Hayward, CA). To standardize for transfection efficiency, the luciferase activities of all transfected cells were divided by the Renilla luciferase activities. Data are presented as mean±S.D. from four separate experiments. Statistical significances were tested by two-way repeated measures ANOVA and Tukey tests for multiple comparisons.

#### 4.9. Zebrafish strains and staging

Embryos were obtained from natural spawning of wild-type (AB-1) zebrafish lines. All developmental stages in this study are reported in hours post-fertilization (hpf) at 28.5 °C (Kimmel et al., 1995).

#### 4.10. MO injections

chx10 translation blocking, and vsx1 splice-blocking MO anti-sense oligonucleotides were obtained from Gene Tools (vsx1 MO: 5'-AGCAAAGTGATTTCGTACCGGAGTAA-3' and chx10 MO: 5'-AAACAGCCCCATCCTTTTCCTGTCAT-3'). Both MOs were injected into one-cell stage wild-type embryos at doses of 1.5 ng and 15 ng, respectively.

#### 4.11. RT-PCR of zebrafish RNA

Fifty wild-type embryos and vsx1 morphants were used for preparing RNA. Total RNA was isolated using Trizol reagent and standard protocols. Total RNA (1–5 µg/µl) was reverse transcribed by either random hexamers or a gene-specific primer using the Superscript first strand synthesis kit (Invitrogen) following the manufacturer's protocol. PCR was performed using an exon 1 forward primer (CGC AAT CAC AGA TCT CCT GG) and an exon 2 reverse primer (TCC ATC ATT GCG ATC ACC GG) for 30–35 cycles using an annealing temperature of 55 °C, and reactions were visualized on 1% agarose gels in TAE.

#### 4.12. In situ hybridization

Probe synthesis and in situ hybridization were performed as described elsewhere (Oxtoby and Jowett, 1993), and visualized using BM Purple (Roche, Indianapolis, IN). The following three RNA probes were used: vsx1 (amplified from published cDNA

sequence (Passini et al., 1997); cycD1 (869 bp PCR fragment); and pax6a (Krauss et al., 1991).

## 5. Note added in proof

As part of an effort to unify and update the nomenclature of human homeobox genes, the HUGO Gene Nomenclature Committee ([www.genenames.org](http://www.genenames.org)) has adopted VSX2 as the official name for the gene previously assigned as CHX10; the mouse ortholog will likewise be Vsx2. Chx10 and Alx (synonym of zebrafish Vsx2) will still be retained in databases to ensure retrieval of all relevant data.

## Acknowledgments

We thank Dr. Sabine Fuhrmann and members of the Levine and Fuhrmann laboratories for their suggestions and insights during the course of this work. We also thank Amy Kircher for her excellent mouse colony management. Funding for this project was generously provided by theResearch to Prevent Blindness, Inc. (Career Development Award to E.M.L.), Knights Templar Eye Foundation (E.M.L.), NEI R01-EY0013760 (E.M.L.), NEI Vision Core Grant EY0014800, Pew Scholars Program (R.I. D.), NINDS R01-NS0053897 (R.I.D.), and Foundation Fighting Blindness, Canada (New Investigator Award to R.L.C.). This work is dedicated to the memory of our friend and colleague, Dr. Kimberly Howes.

## REFERENCES

- Altun-Gultekin, Z., et al., 2001. A regulatory cascade of three homeobox genes, *ceh-10*, *ttx-3* and *ceh-23*, controls cell fate specification of a defined interneuron class in *C. elegans*. *Development* 128, 1951–1969.
- Ashery-Padan, R., Gruss, P., 2001. Pax6 lights-up the way for eye development. *Curr. Opin. Cell Biol.* 13, 706–714.
- Bar-Yosef, U., et al., 2004. CHX10 mutations cause non-syndromic microphthalmia/anophthalmia in Arab and Jewish kindreds. *Hum. Genet.* 115, 302–309.
- Barabino, S.M., et al., 1997. Inactivation of the zebrafish homologue of Chx10 by antisense oligonucleotides causes eye malformations similar to the ocular retardation phenotype. *Mech. Dev.* 63, 133–143.
- Barbaro, V., et al., 2006. Expression of VSX1 in human corneal keratocytes during differentiation into myofibroblasts in response to wound healing. *Investig. Ophthalmol. Vis. Sci.* 47, 5243–5250.
- Bone-Larson, C., et al., 2000. Partial rescue of the ocular retardation phenotype by genetic modifiers. *J. Neurobiol.* 42, 232–247.
- Burmeister, M., et al., 1996. Ocular retardation mouse caused by Chx10 homeobox null allele: impaired retinal progenitor proliferation and bipolar cell differentiation. *Nat. Genet.* 12, 376–384.
- Chen, C.M., Cepko, C.L., 2000. Expression of Chx10 and Chx10-1 in the developing chicken retina. *Mech. Dev.* 90, 293–297.
- Chow, R.L., Lang, R.A., 2001. Early eye development in vertebrates. *Annu. Rev. Cell Dev. Biol.* 17, 255–296.
- Chow, R.L., et al., 2001. Vsx1, a rapidly evolving Paired-like homeobox gene expressed in cone bipolar cells. *Mech. Dev.* 109, 315–322.

- Chow, R.L., et al., 2004. Control of late off-center cone bipolar cell differentiation and visual signaling by the homeobox gene *Vsx1*. *Proc. Natl. Acad. Sci. U. S. A.* 101, 1754–1759.
- Coles, B.L., et al., 2006. Loss of retinal progenitor cells leads to an increase in the retinal stem cell population in vivo. *Eur. J. Neurosci.* 23, 75–82.
- Czerny, T., et al., 1999. Twin of eyeless, a second Pax-6 gene of *Drosophila*, acts upstream of eyeless in the control of eye development. *Mol. Cell* 3, 297–307.
- D'Autilia, S., et al., 2006. Cloning and developmental expression of the *Xenopus* homeobox gene *Xvsx1*. *Dev. Genes Evol.* 216, 829–834.
- de Melo, J., et al., 2003. *Dlx1*, *Dlx2*, *Pax6*, *Brn3b*, and *Chx10* homeobox gene expression defines the retinal ganglion and inner nuclear layers of the developing and adult mouse retina. *J. Comp. Neurol.* 461, 187–204.
- Decembrini, S., et al., 2006. Timing the generation of distinct retinal cells by homeobox proteins. *PLoS Biol.* 4, e272.
- Dhomen, N.S., et al., 2006. Absence of *chx10* causes neural progenitors to persist in the adult retina. *Investig. Ophthalmol. Vis. Sci.* 47, 386–396.
- Dorval, K.M., et al., 2005. Transcriptional activity of the Paired-like homeodomain proteins *CHX10* and *VSX1*. *J. Biol. Chem.* 280, 10100–10108.
- Dorval, K.M., et al., 2006. *CHX10* targets a subset of photoreceptor genes. *J. Biol. Chem.* 281, 744–751.
- Dyer, M.A., 2003. Regulation of proliferation, cell fate specification and differentiation by the homeodomain proteins *Prox1*, *Six3*, and *Chx10* in the developing retina. *Cell Cycle* 2, 350–357.
- Ferda Percin, E., et al., 2000. Human microphthalmia associated with mutations in the retinal homeobox gene *CHX10*. *Nat. Genet.* 25, 397–401.
- Fitzpatrick, D.R., van Heyningen, V., 2005. Developmental eye disorders. *Curr. Opin. Genet. Dev.* 15, 348–353.
- Fuhrmann, S., et al., 2000a. Molecular control of cell diversification in the vertebrate retina. In: Fini, E. (Ed.), *Vertebrate Eye Development*, vol. 31. Springer Verlag, New York, pp. 69–84.
- Fuhrmann, S., et al., 2000b. Extraocular mesenchyme patterns the optic vesicle during early eye development in the embryonic chick. *Development* 127, 4599–4609.
- Furukawa, T., et al., 1997. *Rax*, a novel Paired-type homeobox gene, shows expression in the anterior neural fold and developing retina. *Proc. Natl. Acad. Sci. U. S. A.* 94, 3088–3093.
- Galliot, B., et al., 1999. Evolution of homeobox genes: Q50 Paired-like genes founded the paired class. *Dev. Genes Evol.* 209, 186–197.
- Gotoh, N., et al., 2004. Tyrosine phosphorylation sites on *FRS2alpha* responsible for *Shp2* recruitment are critical for induction of lens and retina. *Proc. Natl. Acad. Sci. U. S. A.* 101, 17144–17149.
- Graw, J., 2003. The genetic and molecular basis of congenital eye defects. *Nat. Rev., Genet.* 4, 876–888.
- Green, E.S., et al., 2003. Genetic rescue of cell number in a mouse model of microphthalmia: interactions between *Chx10* and *G1-phase* cell cycle regulators. *Development* 130, 539–552.
- Hanson, I.M., 2001. Mammalian homologues of the *Drosophila* eye specification genes. *Semin. Cell Dev. Biol.* 12, 475–484.
- Hatakeyama, J., et al., 2004. *Hes* genes regulate size, shape and histogenesis of the nervous system by control of the timing of neural stem cell differentiation. *Development* 131, 5539–5550.
- Hayashi, T., et al., 2000. *RINX(VSX1)*, a novel homeobox gene expressed in the inner nuclear layer of the adult retina. *Genomics* 67, 128–139.
- Heon, E., et al., 2002. *VSX1*: a gene for posterior polymorphous dystrophy and keratoconus. *Hum. Mol. Genet.* 11, 1029–1036.
- Horsford, D.J., et al., 2005. *Chx10* repression of *Mitf* is required for the maintenance of mammalian neuroretinal identity. *Development* 132, 177–187.
- Hyer, J., et al., 1998. *FGF1* patterns the optic vesicle by directing the placement of the neural retina domain. *Development* 125, 869–877.
- Kimmel, C.B., et al., 1995. Stages of embryonic development of the zebrafish. *Dev. Dyn.* 203, 253–310.
- Knauer, S.K., et al., 2005. Nuclear export is evolutionarily conserved in CVC Paired-like homeobox proteins and influences protein stability, transcriptional activation, and extracellular secretion. *Mol. Cell. Biol.* 25, 2573–2582.
- Krauss, S., et al., 1991. Zebrafish *pax[zf-a]*: a paired box-containing gene expressed in the neural tube. *EMBO J.* 10, 3609–3619.
- Kurtzman, A.L., Schechter, N., 2001. *Ubc9* interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein *Vsx-1* independent of *SUMO-1* modification. *Proc. Natl. Acad. Sci. U. S. A.* 98, 5602–5607.
- Levine, E.M., Green, E.S., 2004. Cell-intrinsic regulators of proliferation in vertebrate retinal progenitors. *Semin. Cell Dev. Biol.* 15, 63–74.
- Levine, E.M., et al., 1994. Restricted expression of a new paired-class homeobox gene in normal and regenerating adult goldfish retina. *J. Comp. Neurol.* 348, 596–606.
- Liu, I.S., et al., 1994. Developmental expression of a novel murine homeobox gene (*Chx10*): evidence for roles in determination of the neuroretina and inner nuclear layer. *Neuron* 13, 377–393.
- Livne-Bar, I., et al., 2006. *Chx10* is required to block photoreceptor differentiation but is dispensable for progenitor proliferation in the postnatal retina. *Proc. Natl. Acad. Sci. U. S. A.* 103, 4988–4993.
- Loosli, F., et al., 2001. Medaka *eyeless* is the key factor linking retinal determination and eye growth. *Development* 128, 4035–4044.
- Lupo, G., et al., 2000. Homeobox genes in the genetic control of eye development. *Int. J. Dev. Biol.* 44, 627–636.
- Mastick, G.S., et al., 1997. *Pax-6* functions in boundary formation and axon guidance in the embryonic mouse forebrain. *Development* 124, 1985–1997.
- Mintz-Hittner, H.A., et al., 2004. *VSX1 (RINX)* mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells. *Ophthalmology* 111, 828–836.
- Murali, D., et al., 2005. Distinct developmental programs require different levels of *Bmp* signaling during mouse retinal development. *Development* 132, 913–923.
- Nguyen, M., Arnheiter, H., 2000. Signaling and transcriptional regulation in early mammalian eye development: a link between *FGF* and *MITF*. *Development* 127, 3581–3591.
- Ohtoshi, A., et al., 2001. Isolation and characterization of *Vsx1*, a novel mouse CVC paired-like homeobox gene expressed during embryogenesis and in the retina. *Biochem. Biophys. Res. Commun.* 286, 133–140.
- Ohtoshi, A., et al., 2004. Regulation of retinal cone bipolar cell differentiation and photopic vision by the CVC homeobox gene *Vsx1*. *Curr. Biol.* 14, 530–536.
- Oxtoby, E., Jowett, T., 1993. Cloning of the zebrafish *krox-20* gene (*krx-20*) and its expression during hindbrain development. *Nucleic Acids Res.* 21, 1087–1095.
- Passini, M.A., et al., 1997. *Vsx-1* and *Vsx-2*: differential expression of two paired-like homeobox genes during zebrafish and goldfish retinogenesis. *J. Comp. Neurol.* 388, 495–505.
- Passini, M.A., et al., 1998. Cloning of zebrafish *vsx1*: expression of a paired-like homeobox gene during CNS development. *Dev. Genet.* 23, 128–141.
- Plouhinec, J.L., et al., 2005. Comparative analysis of gnathostome *Otx* gene expression patterns in the developing eye: implications for the functional evolution of the multigene family. *Dev. Biol.* 278, 560–575.
- Rowan, S., Cepko, C.L., 2004. Genetic analysis of the homeodomain transcription factor *Chx10* in the retina using a novel multifunctional BAC transgenic mouse reporter. *Dev. Biol.* 271, 388–402.
- Rowan, S., Cepko, C.L., 2005. A POU factor binding site upstream of

- the Chx10 homeobox gene is required for Chx10 expression in subsets of retinal progenitor cells and bipolar cells. *Dev. Biol.* 281, 240–255.
- Rowan, S., et al., 2004. Transdifferentiation of the retina into pigmented cells in ocular retardation mice defines a new function of the homeodomain gene Chx10. *Development* 131, 5139–5152.
- Rutherford, A.D., et al., 2004. Delayed expression of the Crx gene and photoreceptor development in the Chx10-deficient retina. *Investig. Ophthalmol. Vis. Sci.* 45, 375–384.
- Svendsen, P.C., McGhee, J.D., 1995. The *C. elegans* neuronally expressed homeobox gene *ceh-10* is closely related to genes expressed in the vertebrate eye. *Development* 121, 1253–1262.
- Theiler, K., et al., 1976. A new allele of ocular retardation: early development and morphogenetic cell death. *Anat. Embryol. (Berl)* 150, 85–97.
- Toy, J., et al., 2002. Effects of homeobox genes on the differentiation of photoreceptor and nonphotoreceptor neurons. *Investig. Ophthalmol. Vis. Sci.* 43, 3522–3529.
- Valleix, S., et al., 2006. H244R VSX1 is associated with selective cone ON bipolar cell dysfunction and macular degeneration in a PCD family. *Investig. Ophthalmol. Vis. Sci.* 47, 48–54.
- Winkler, S., et al., 2000. The conditional medaka mutation *eyeless* uncouples patterning and morphogenesis of the eye. *Development* 127, 1911–1919.
- Xiang, M., et al., 1993. Brn-3b: a POU domain gene expressed in a subset of retinal ganglion cells. *Neuron* 11, 689–701.
- Yamada, R., et al., 2004. Requirement for Mab21l2 during development of murine retina and ventral body wall. *Dev. Biol.* 274, 295–307.
- Zuber, M.E., et al., 2003. Specification of the vertebrate eye by a network of eye field transcription factors. *Development* 130, 5155–5167.